Kestra Investment Management LLC Grows Holdings in Johnson & Johnson $JNJ

Kestra Investment Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 38.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,658 shares of the company’s stock after acquiring an additional 9,552 shares during the period. Kestra Investment Management LLC’s holdings in Johnson & Johnson were worth $5,294,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Clark Asset Management LLC lifted its position in Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after buying an additional 3,025 shares in the last quarter. Apexium Financial LP lifted its holdings in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after buying an additional 2,310 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the last quarter. Avanza Fonder AB grew its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Finally, Winnow Wealth LLC acquired a new position in Johnson & Johnson during the second quarter worth $295,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on JNJ shares. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Barclays upped their target price on Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $207.55.

Johnson & Johnson Trading Up 0.8%

Johnson & Johnson stock opened at $211.65 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $212.27. The stock has a market cap of $509.93 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The business has a 50 day moving average price of $196.09 and a two-hundred day moving average price of $177.25. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.